Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Assets (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Assets for 5 consecutive years, with $76.6 million as the latest value for Q4 2025.

  • For Q4 2025, Assets fell 47.02% year-over-year to $76.6 million; the TTM value through Dec 2025 reached $76.6 million, down 47.02%, while the annual FY2025 figure was $76.6 million, 47.02% down from the prior year.
  • Assets hit $76.6 million in Q4 2025 for Kezar Life Sciences, down from $97.7 million in the prior quarter.
  • Across five years, Assets topped out at $317.5 million in Q2 2022 and bottomed at $76.6 million in Q4 2025.
  • Average Assets over 5 years is $196.5 million, with a median of $189.5 million recorded in 2024.
  • Year-over-year, Assets surged 132.85% in 2022 and then crashed 47.02% in 2025.
  • Kezar Life Sciences' Assets stood at $217.9 million in 2021, then surged by 37.46% to $299.6 million in 2022, then fell by 26.15% to $221.2 million in 2023, then crashed by 34.6% to $144.7 million in 2024, then plummeted by 47.02% to $76.6 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $76.6 million, $97.7 million, and $109.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.